topic

Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression
N Nora Bennani, Hyo Jin Kim, Levi D Pederson, Pamela J Atherton, Ivana N Micallef, Gita Thanarajasingam, Grzegorz S Nowakowski, Thomas Witzig, Andrew L Feldman, Stephen M Ansell

Journal for ImmunoTherapy of Cancer Jun 2022, 10 (6) e004984; DOI: 10.1136/jitc-2022-004984
Antibody-based redirection of universal Fabrack-CAR T cells selectively kill antigen bearing tumor cells
Yi-Chiu Kuo, Cheng-Fu Kuo, Kurt Jenkins, Alfur Fu-Hsin Hung, Wen-Chung Chang, Miso Park, Brenda Aguilar, Renate Starr, Jonathan Hibbard, Christine Brown, John C Williams

Journal for ImmunoTherapy of Cancer Jun 2022, 10 (6) e003752; DOI: 10.1136/jitc-2021-003752
Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies
Christine M Minnar, Paul L Chariou, Lucas A Horn, Kristin C Hicks, Claudia Palena, Jeffrey Schlom, Sofia R Gameiro

Journal for ImmunoTherapy of Cancer Jun 2022, 10 (6) e004561; DOI: 10.1136/jitc-2022-004561
T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma
Xuefeng Wang, Jameel Muzaffar, Kedar Kirtane, Feifei Song, Matthew Johnson, Michael J Schell, Jiannong Li, Sean J Yoder, Jose R Conejo-Garcia, Jose A Guevara-Patino, Marcelo Bonomi, Priyanka Bhateja, James W Rocco, Conor E Steuer, Nabil F Saba, Christine H Chung

Journal for ImmunoTherapy of Cancer Jun 2022, 10 (6) e004512; DOI: 10.1136/jitc-2022-004512
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)
Hussein A Tawbi, Caroline Robert, Jan C Brase, Daniel Gusenleitner, Eduard Gasal, James Garrett, Alexander Savchenko, Güllü Görgün, Keith T Flaherty, Antoni Ribas, Reinhard Dummer, Dirk Schadendorf, Georgina V Long, Paul D Nathan, Paolo A Ascierto

Journal for ImmunoTherapy of Cancer Jun 2022, 10 (6) e004226; DOI: 10.1136/jitc-2021-004226
Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade
Won Suk Lee, Dong Sung Kim, Jeong Hun Kim, Yoonki Heo, Hannah Yang, Eun-Jin Go, Jin Hyoung Kim, Seung Joon Lee, Byung Cheol Ahn, Jung Sun Yum, Hong Jae Chon, Chan Kim

Journal for ImmunoTherapy of Cancer Jun 2022, 10 (6) e004799; DOI: 10.1136/jitc-2022-004799
Inhaled recombinant human IL-15 in dogs with naturally occurring pulmonary metastases from osteosarcoma or melanoma: a phase 1 study of clinical activity and correlates of response
Robert B Rebhun, Daniel York, Sylvia Margret Cruz, Sean J Judge, Aryana M Razmara, Lauren E Farley, Rachel V Brady, Eric G Johnson, Jenna H Burton, Jennifer Willcox, Luke A Wittenburg, Kevin Woolard, Cordelia Dunai, Susan L Stewart, Ellen E Sparger, Sita S Withers, Alicia A Gingrich, Katherine A Skorupski, Sami Al-Nadaf, Amandine T LeJeune, William TN Culp, William J Murphy, Michael S Kent, Robert J Canter

Journal for ImmunoTherapy of Cancer Jun 2022, 10 (6) e004493; DOI: 10.1136/jitc-2022-004493
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study
Brett Marinelli, Edward Kim, Antonio D'Alessio, Mario Cedillo, Ishan Sinha, Neha Debnath, Masatoshi Kudo, Naoshi Nishida, Anwaar Saeed, Hannah Hildebrand, Ahmed O Kaseb, Yehia I Abugabal, Anjana Pillai, Yi-Hsiang Huang, Uqba Khan, Mahvish Muzaffar, Abdul Rafeh Naqash, Rahul Patel, Aaron Fischman, Vivian Bishay, Dominik Bettinger, Max Sung, Celina Ang, Myron Schwartz, David J Pinato, Thomas Marron

Journal for ImmunoTherapy of Cancer Jun 2022, 10 (6) e004205; DOI: 10.1136/jitc-2021-004205
WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma
Rosa A van Amerongen, Renate S Hagedoorn, Dennis F G Remst, Danique C Assendelft, Dirk M van der Steen, Anne K Wouters, Marian van de Meent, Michel G D Kester, Arnoud H de Ru, Marieke Griffioen, Peter A van Veelen, J H Frederik Falkenburg, Mirjam H M Heemskerk

Journal for ImmunoTherapy of Cancer Jun 2022, 10 (6) e004409; DOI: 10.1136/jitc-2021-004409
Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors
Daniel V Kalinovsky, Alexey V Kibardin, Irina V Kholodenko, Elena V Svirshchevskaya, Igor I Doronin, Mariya V Konovalova, Maria V Grechikhina, Fedor N Rozov, Sergey S Larin, Sergey M Deyev, Roman V Kholodenko

Journal for ImmunoTherapy of Cancer Jun 2022, 10 (6) e004646; DOI: 10.1136/jitc-2022-004646

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages